Our Business
Accelerating access to affordable, high-quality, and innovative medicines across global communities.
Division 01
India Business
Deep local penetration and trusted healthcare leadership
BLPL GORUP of Company have good strength in manufacturing & exporting, a tested trusted name in Indian pharmaceutical Industry. We are a rapidly associate growing Indian pharmaceutical manufacturing company with a strong presence in Tablets (Beta, Cefa & General), Capsules, Liquid, Ointment, Injectable (dry & liquid), Opthalmic Solution (Eye Drops & Nsal Drops), and marketing. We follow revised WHO-GMP guidelines that have been certified & \accredited for Good Manufacturing Practise (GMP).
- Manufacturing : Well designed infrastructure to carry out aseptic production. Each area comprises of the hygiene classes of grades B, C, D controlled area & comfort zone.
- Process : Fully automatic process in injectable.
- Machines : High speed machineries for optimised output.
- Quality control : Well equipped quality control lab with GLP Accreditation.
- Ultra modern Ancillary area
Division 02
Emerging Markets
Accelerating global access to critical therapeutic alternatives
We are expanding our presence in high-growth global territories, including Latin America, South Africa, and Southeast Asia. BioShastra aims to bypass historical trade limits by delivering high-fidelity bio-equivalent complex generics. Our localization strategy leverages partnerships and regulatory agility to deliver medicines quickly and safely.
- Direct registration footprints in Brazil, Chile, and South Africa.
- Local distribution partnerships across 30+ Emerging Economies.
- Low-friction supply pathways for critical active agents.
Division 03
Investing for Future Generations
Next-gen Biosimilars, Biologics, and AI Drug Simulations
The future of therapeutics belongs to biologics. At BioShastra, we are investing in high-yield biosimilar pipelines targeting oncology and chronic autoimmune disorders. By employing AI-driven sub-angstrom variant predictions, we cut development times in half, ensuring affordable, state-of-the-art biotherapeutic treatments for generations to come.
- Advanced oncology and immunology biosimilars in active development.
- In-silico deep learning molecular simulation suites.
- Open-innovation co-development contracts for complex biologics.
